Analyst firms · Wolfe Research · PODD

Wolfe Research PODD price target and rating history

Insulet Corporation (PODD) · Health Care

Wolfe Research rates Insulet Corporation (PODD) Outperform with a $350 price target, as of its latest action on May 13, 2025. It has published 4 rating actions on PODD since January 2023, including 2 upgrades and 1 downgrade. Across 10 firms with a PODD price target in the last 12 months, the median target is $182.

Current rating
Outperform
Price target
$350
Median target, all firms
$182
Actions on PODD
4

Wolfe Research price target on PODD

$350$275$20020252026
Wolfe Research price target on PODD, each point a stated target, May 2024 to May 2025.

Every Wolfe Research rating on PODD

How other firms rate PODD

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysEqual Weight$150Oct 7, 2026
Truist SecuritiesHold$153Aug 6, 2026
Wells FargoEqual Weight$144Aug 6, 2026
BTIGNeutralAug 6, 2026
Leerink PartnersMarket Perform$145Aug 6, 2026
OppenheimerPerformAug 5, 2026
UBSNeutral$174Jul 28, 2026
Deutsche BankBuy$190Jun 23, 2026
William BlairOutperformMay 20, 2026
Rothschild & Co RedburnNeutral$220Apr 24, 2026
CitigroupNeutral$230Apr 7, 2026
TD CowenHold$294Jan 27, 2026
Evercore ISIOutperform$370Dec 16, 2025

Questions about Wolfe Research and PODD

What is Wolfe Research's price target for PODD?
Wolfe Research's latest stated price target for Insulet Corporation (PODD) is $350, from its action on May 13, 2025.
What is Wolfe Research's rating on PODD?
Wolfe Research rates PODD Outperform, a bullish rating, as of May 13, 2025.
When did Wolfe Research last change its view on PODD?
On May 13, 2025, Wolfe Research upgrades to Outperform from Peer Perform, price target $350.
How does Wolfe Research's PODD target compare with other analysts?
Across 10 firms with a PODD price target in the last 12 months, the median target is $182.

More PODD rating histories

All Wolfe Research ratingsPODD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.